ClinicalTrials.gg
CompletedNCT00661713Updated Mar 20, 2019Results posted

Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules

A Phase 2/3 interventional study of rMenB+OMV NZ and Placebo in Meningococcal Disease, sponsored by Novartis Vaccines. Completed at 10 sites in Chile. Open to participants aged 11 Years to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-03-20.

Sponsored by Novartis Vaccines (formerly part of Novartis) · Phase 2/3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
1,631
Allocation
Randomized
Ages
11 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing 4CMenB vaccine in Meningococcal Infections — 1 open to participants now, 2 under way, none of them phase 3. 4CMenB vaccine · Meningococcal Infections.

Enrollment
4th of 21
1,631 · median 508
Started
2008
with 1 other
Phase 2/3
2 of 21
none open now
Registered
3rd of 21
by date
Lead sponsor
10 of 21
Novartis Vaccines

Among the 21 studies testing 4CMenB vaccine in Meningococcal Infections, this one is the 4th largest by enrollment, is one of 2 that started in 2008, is one of 2 in phase 2/3, and was the 3rd registered.

Meningococcal Infections

243 studies on the registry are indexed under Meningococcal Infections; 8 are open to participants now.

Browse Meningococcal Infections studies →

Open to participants now

1 of the 21 studies testing 4CMenB vaccine in Meningococcal Infections is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About 4CMenB vaccine

4CMenB vaccine: first FDA approval 2014 (Trumenba). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 7 Meningococcal Infections studies recruiting now, 3 set no upper age limit and 4 stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.

This study: 11 Years to 17 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing 4CMenB vaccine in Meningococcal Infections, or all of them as a file.
02

Study summary

The proposed study is aimed to assess the antibody response and short-term persistence of Novartis Meningococcal B Vaccine after one, two or three doses and to evaluate the optimal vaccination schedule in an adolescent population.

03

Conditions studied

  • Meningococcal Disease

Keywords

  • Meningococcal disease
  • Neisseria meningitidis serogroup B
  • prevention
  • vaccination
  • adolescents
04

Who can participate

Ages eligible
11 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1)11-17 years of age inclusive who have given their written assent and whose parents or legal guardians have given written at the time of enrollment;

2)who are available for all the visits scheduled in the study (i.e., not planning to leave the area before the end of the study period);

3)in good health as determined by the outcome of medical history, physical examination and clinical judgment of the investigator.

Exclusion criteria

Exclusion Criteria:

  1. History of any meningococcal B vaccine administration;
  2. Current or previous, confirmed or suspected disease caused by N. meningitidis;
  3. Household contact with and/or intimate exposure to an individual with any laboratory confirmed N. meningitidis infection within 60 days of enrollment;
  4. Significant acute or chronic infection within the previous 7 days or fever (defined as axillary temperature ≥38°C) within the previous day;
  5. Antibiotics within 6 days prior to enrollment;
  6. Pregnancy or nursing (breastfeeding) mothers;
  7. Females of childbearing age who have not used or do not plan to use acceptable measures, for the 7 months duration of the study. Oral, injected or implanted hormonal contraceptive, diaphragm, condom, intrauterine device or sexual abstinence are considered acceptable forms of birth control. If sexually active the subject must have been using one of the accepted birth control methods at least two months prior to study entry;
  8. Any serious chronic or progressive disease (e.g., neoplasm, diabetes, cardiac disease, hepatic disease, progressive neurological disease or seizure disorder; disease, infection or AIDS, or blood dyscrasias or diathesis, signs of cardiac or renal failure or severe malnutrition).
  9. Known or suspected impairment/alteration of the immune system, therapy, including use of in immunosuppressive doses or chronic use of inhaled high-potency corticosteroids within the previous 60 days. [Use of topical corticosteroids administered during the study in limited areas (i.e., eczema on knees or face or elbows) of the body is allowed]; immunostimulants;
  10. Receipt of blood, blood products and/or plasma derivatives, or a parenteral immunoglobulin preparation within the previous 90 days;
  11. History of severe allergic reactions after previous vaccinations or to any vaccine component;
  12. Receipt of or intent to immunize with any other vaccine(s) within 30 days prior (60 days for live viral vaccines) and throughout the study period (exception: licensed fluvaccine should not be administered within 14 days prior to enrollment; routine vaccine administration may be administered after the blood draw at Study Month 7);
  13. Participation in another clinical trial within the last 90 days or planned for during study;
  14. Family members and household members of research staff;
  15. Any condition which in the opinion of the investigator and/or the Regional MD may interfere with the evaluation of the study objectives.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
1,631 participants (actual)

Study arms

  • Experimental
    rMenB06

    Subjects received one injection of rMenB+OMV NZ vaccine (month 0) and two injections of placebo (at month 1, month 2). A second injection of rMenB+OMV NZ vaccine was given later (month 6).

    Biological: rMenB+OMV NZ · Biological: Placebo

  • Experimental
    rMenB0

    Subjects received one injection of rMenB+OMV NZ vaccine (month 0) and three injections of placebo (month 1, month 2 and month 6).

    Biological: rMenB+OMV NZ · Biological: Placebo

  • Experimental
    rMenB016

    Subjects received two injections of rMenB+OMV NZ vaccine (at month 0 and month 1) and one injection of placebo (at month 2). A third injection of rMenB+OMV NZ vaccine was given later (at month 6).

    Biological: rMenB+OMV NZ · Biological: Placebo

  • Experimental
    rMenB01

    Subjects received two injections of rMenB+OMV NZ vaccine (at month 0 and month 1) and two injection of placebo (at month 2 and month 6).

    Biological: rMenB+OMV NZ · Biological: Placebo

  • Experimental
    rMenB026

    Subjects received two injections of rMenB+OMV NZ vaccine (at month 0 and month 2) and one injection of placebo (at month 2). A third injection of rMenB+OMV NZ vaccine was given later (at month 6).

    Biological: rMenB+OMV NZ · Biological: Placebo

  • Experimental
    rMenB02

    Subjects received two injections of rMenB+OMV NZ vaccine (at month 0 and month 2) and two injections of placebo (at month 1 and month 6).

    Biological: rMenB+OMV NZ · Biological: Placebo

  • Experimental
    rMenB012

    Subjects received three injections of rMenB+OMV NZ vaccine (at month 0, month 1 and month 2) and one injection of placebo later (at month 6).

    Biological: rMenB+OMV NZ · Biological: Placebo

  • Experimental
    rMenB6

    Subjects received three injections of placebo(at month 0, month 1 and month 2) and one injection of rMenB+OMV NZ vaccine(at month 6).

    Biological: rMenB+OMV NZ · Biological: Placebo

Interventions

  • BiologicalrMenB+OMV NZ

    Drug page: 4CMenB vaccine

    Also known as: Serogroup B Meningococcal Vaccine

  • BiologicalPlacebo
06

What researchers measure

Primary outcomes

  1. Percentages of Subjects With hSBA Titer ≥1:4 After Receiving One, Two or Three Doses of rMenB+OMV NZ Vaccine.

    Immunogenicity was evaluated by measuring the percentage of subjects with hSBA titter \>1:4 against 44/76-SL, 5/99, NZ98/254 strains at months 1, 2, 3.

    Time frame: Month-1, 2, 3

  2. Number of Subjects With Local Reactions and Systemic Reactions Occurring in Days 1 to 7 After Vaccination

    Safety was assessed as the number of subjects who reported local and systemic reactions during day 1 to day 7 after any vaccination with rMenB+OMV

    Time frame: 1 to 7 days after each vaccination

Secondary outcomes

  1. Percentages of Subjects With hSBA Titer ≥1:4 After Receiving a Booster Dose of rMenB+OMV NZ Vaccine at Month 6.

    Immunogenicity was evaluated by measuring the percentage of subjects with hSBA titter \>1:4 agains 44/76-SL, 5/99, NZ98/254 strains at months 6 \& 7.

    Time frame: Month-6 & 7

  2. Percentage of Subjects With hSBA Titer ≥1:8 After Primary and Booster Vaccination.

    Immunogenicity was evaluated by measuring the percentage of subjects with hSBA titer ≥1:8 against 44/76-SL, 5/99, NZ98/254 strains.

    Time frame: at baseline, month-1, month-2, month-3, month-6 and month-7.

  3. Percentages of Subjects With at Least a Fourfold Rise in hSBA Titer Over the Prevaccination and After Booster Vaccination.

    Immunogenicity was evaluated by measuring the percentage of subjects with at least a fourfold rise in hSBA titer over the prevaccination and after booster vaccination against 44/76-SL, 5/99, NZ98/254 strains at month-1, month-2, month-3 and month-7.

    Time frame: Month-1, month-2, month-3 and month-7

  4. Geometric Mean Titers (GMTs) After Primary and Booster Vaccination.

    Immunogenicity was evaluated by measuring the Geometric mean titers (GMTs) after primary and booster vaccination against 44/76-SL, 5/99, NZ98/254.

    Time frame: month-1, month-2, month-3, month-6 and month-7

  5. Geometric Mean Ratios (GMRs) After Primary and Booster Vaccination.

    Immunogenicity was evaluated by measuring the Geometric mean ratios (GMRs) after primary and booster vaccination against 44/76-SL, 5/99, NZ98/254.

    Time frame: month-1, month-2, month-3, month-6 and month-7

  6. GMCs of Antibodies Against 287-953Antigen (ELISA) After Primary and Booster Vaccination.

    Immunogenicity was evaluated by measuring the Geometric mean Concentration (GMCs) after primary and booster vaccination against Antigen 287-953 Antigen.

    Time frame: month-1, month-2, month-3, month-6 and month-7

  7. GMRs of Antibodies Against 287-953Antigen (ELISA) After Primary and Booster Vaccination

    Immunogenicity was evaluated by measuring the Geometric mean Ratios (GMRs) after primary and booster vaccination against 287-953Antigen

    Time frame: month-1, month-2, month-3, month-6 and month-7

  8. Number of Subjects Reporting Unsolicited AEs Throughout the Study.

    Safety was assessed as the number of subjects who reported unsolicited AEs throughout the study.

    Time frame: Throughout the study

07

Results

Posted Nov 4, 2015

Participant flow

Subjects were enrolled at 10 study centers in Chile.

Participant flow — Overall Study
MilestonerMenB06rMenB0rMenB016rMenB01rMenB026rMenB02rMenB012rMenB6
Started128247128247127253373128
Completed112208111219107216309117
Not completed1639172820376411
Withdrew: Death10001000
Withdrew: Unable to classify10000000
Withdrew: Protocol violation16330221
Withdrew: Withdrawal by subject112512211226459
Withdrew: Lost to follow-up272257141
Withdrew: Administrative reason01022210
Withdrew: Adverse event00000010
Withdrew: Inappropriate enrollment00000010

Outcome measures

PrimaryPercentages of Subjects With hSBA Titer ≥1:4 After Receiving One, Two or Three Doses of rMenB+OMV NZ Vaccine.

Immunogenicity was evaluated by measuring the percentage of subjects with hSBA titter \>1:4 against 44/76-SL, 5/99, NZ98/254 strains at months 1, 2, 3.

Time frame:
Month-1, 2, 3
Reported as:
Number · percentage of Subjects
Percentages of Subjects With hSBA Titer ≥1:4 After Receiving One, Two or Three Doses of rMenB+OMV NZ Vaccine.
percentage of SubjectsrMenB06rMenB0rMenB016rMenB01rMenB026rMenB02rMenB012rMenB6
44/76-SL- Mo 042 (33 to 52)47 (40 to 54)41 (32 to 50)38 (32 to 45)37 (28 to 47)47 (40 to 53)46 (41 to 52)46 (36 to 55)
44/76-SL- Mo 192 (85 to 96)92 (88 to 95)95 (89 to 98)93 (88 to 96)90 (83 to 95)92 (88 to 95)95 (92 to 97)43 (34 to 53)
44/76-SL- Mo 288 (80 to 93)92 (88 to 95)100 (97 to 100)100 (98 to 100)88 (80 to 93)89 (85 to 93)100 (98 to 100)50 (40 to 59)
44/76-SL- Mo 384 (76 to 90)88 (82 to 92)99 (95 to 100)100 (97 to 100)100 (97 to 100)100 (98 to 100)100 (98 to 100)48 (38 to 58)
5/99- Mo 029 (20 to 38)41 (35 to 48)28 (20 to 38)31 (25 to 38)30 (22 to 39)37 (31 to 44)36 (30 to 41)29 (21 to 38)
5/99- Mo 197 (92 to 99)96 (93 to 98)96 (90 to 99)97 (94 to 99)97 (92 to 99)95 (92 to 98)97 (94 to 98)35 (26 to 44)
5/99- Mo 295 (90 to 98)94 (90 to 97)100 (97 to 100)100 (98 to 100)97 (92 to 99)96 (93 to 98)100 (98 to 100)31 (23 to 41)
5/99- Mo 392 (85 to 96)89 (84 to 93)99 (95 to 100)100 (98 to 100)98 (93 to 100)100 (98 to 100)100 (99 to 100)32 (24 to 42)
NZ98/254-mo 032 (24 to 42)39 (33 to 46)33 (24 to 42)35 (29 to 41)34 (25 to 43)37 (31 to 44)33 (28 to 38)38 (29 to 47)
NZ98/254-mo 190 (83 to 95)94 (90 to 97)95 (89 to 98)94 (90 to 96)90 (83 to 95)93 (89 to 96)95 (92 to 97)38 (29 to 48)
NZ98/254-mo 281 (73 to 88)84 (74 to 88)99 (95 to 100)100 (98 to 100)78 (69 to 86)85 (79 to 89)100 (98 to 100)39 (29 to 48)
NZ98/254-mo 380 (72 to 87)76 (70 to 82)97 (92 to 99)97 (94 to 99)100 (97 to 100)100 (98 to 100)99 (97 to 100)43 (33 to 52)
PrimaryNumber of Subjects With Local Reactions and Systemic Reactions Occurring in Days 1 to 7 After Vaccination

Safety was assessed as the number of subjects who reported local and systemic reactions during day 1 to day 7 after any vaccination with rMenB+OMV

Time frame:
1 to 7 days after each vaccination
Reported as:
Number · participants
Number of Subjects With Local Reactions and Systemic Reactions Occurring in Days 1 to 7 After Vaccination
participantsrMenB06rMenB0rMenB016rMenB01rMenB026rMenB02rMenB012rMenB6
erythema (local)93162951889417228285
Induration (Local)71130751518212122857
Swelling (Local)72132811447611522654
Pain (Local)122236124237113236345123
Med.Att Fever (Systemic)10201111
Malaise (Systemic)92181961728718527289
Myalgia(Systemic)85141911568116023891
Arthralgia(Systemic)557655803910514643
Headache(Systemic)79139881607316524474
Nausea(Systemic)41805172428814349
Fever(Systemic)128112118263818
SecondaryPercentages of Subjects With hSBA Titer ≥1:4 After Receiving a Booster Dose of rMenB+OMV NZ Vaccine at Month 6.

Immunogenicity was evaluated by measuring the percentage of subjects with hSBA titter \>1:4 agains 44/76-SL, 5/99, NZ98/254 strains at months 6 \& 7.

Time frame:
Month-6 & 7
Reported as:
Number · percentage of Subjects
Percentages of Subjects With hSBA Titer ≥1:4 After Receiving a Booster Dose of rMenB+OMV NZ Vaccine at Month 6.
percentage of SubjectsrMenB06rMenB0rMenB016rMenB01rMenB026rMenB02rMenB012rMenB6
44/76-SL- Mo 676 (66 to 84)72 (65 to 79)93 (86 to 97)92 (88 to 96)97 (91 to 99)98 (94 to 99)97 (94 to 99)46 (36 to 56)
44/76-SL- Mo 7100 (96 to 100)71 (64 to 78)100 (96 to 100)90 (85 to 94)100 (96 to 100)95 (91 to 98)95 (92 to 98)93 (85 to 97)
5/99- Mo 679 (70 to 87)74 (67 to 80)99 (95 to 100)98 (96 to 100)99 (95 to 100)100 (97 to 100)100 (98 to 100)28 (19 to 38)
5/99- Mo 799 (94 to 100)67 (60 to 74)100 (96 to 100)98 (95 to 99)100 (96 to 100)99 (96 to 100)99 (97 to 100)93 (85 to 97)
NZ98/254-mo 681 (72 to 88)69 (62 to 76)93 (86 to 97)89 (84 to 93)97 (91 to 99)96 (92 to 98)97 (94 to 99)45 (35 to 55)
NZ98/254-mo 7100 (96 to 100)67 (60 to 74)100 (96 to 100)85 (79 to 90)100 (96 to 100)94 (89 to 97)95 (92 to 98)93 (85 to 97)
SecondaryPercentage of Subjects With hSBA Titer ≥1:8 After Primary and Booster Vaccination.

Immunogenicity was evaluated by measuring the percentage of subjects with hSBA titer ≥1:8 against 44/76-SL, 5/99, NZ98/254 strains.

Time frame:
at baseline, month-1, month-2, month-3, month-6 and month-7.
Reported as:
Number · percentage of Subjects
Percentage of Subjects With hSBA Titer ≥1:8 After Primary and Booster Vaccination.
percentage of SubjectsrMenB06rMenB0rMenB016rMenB01rMenB026rMenB02rMenB012rMenB6
44/76-SL- Mo 029 (21 to 39)37 (31 to 44)31 (23 to 40)32 (26 to 38)30 (22 to 39)35 (29 to 42)33 (28 to 38)33 (24 to 42)
44/76-SL- Mo 187 (79 to 92)87 (82 to 91)85 (77 to 91)85 (80 to 89)81 (72 to 88)87 (82 to 91)86 (82 to 90)30 (22 to 40)
44/76-SL- Mo 279 (70 to 86)84 (78 to 89)99 (95 to 100)99 (97 to 100)80 (71 to 87)80 (74 to 85)99 (98 to 100)33 (24 to 43)
44/76-SL- Mo 374 (64 to 82)77 (71 to 83)99 (95 to 100)98 (95 to 99)99 (95 to 100)100 (98 to 100)99 (97 to 100)36 (27 to 46)
44/76-SL- Mo 662 (52 to 72)62 (54 to 69)90 (82 to 95)83 (77 to 88)90 (82 to 95)91 (86 to 95)93 (90 to 96)34 (25 to 44)
44/76-SL- Mo 799 (94 to 100)57 (49 to 64)100 (96 to 100)82 (75 to 87)100 (96 to 100)88 (82 to 92)91 (86 to 94)89 (81 to 95)
5/99- Mo 018 (11 to 26)24 (19 to 30)20 (13 to 29)22 (17 to 28)23 (15 to 32)22 (17 to 28)22 (17 to 26)14 (8 to 21)
5/99- Mo 196 (91 to 99)91 (87 to 95)89 (82 to 94)94 (90 to 96)91 (84 to 96)93 (89 to 96)94 (91 to 96)19 (12 to 28)
5/99- Mo 289 (81 to 94)85 (80 to 90)100 (97 to 100)100 (98 to 100)78 (69 to 86)88 (83 to 92)99 (98 to 100)17 (11 to 26)
5/99- Mo 381 (73 to 88)77 (71 to 83)99 (95 to 100)100 (97 to 100)98 (93 to 100)100 (98 to 100)100 (99 to 100)19 (12 to 27)
5/99- Mo 660 (50 to 70)57 (50 to 64)97 (91 to 99)98 (95 to 99)98 (93 to 100)99 (96 to 100)99 (97 to 100)16 (9 to 25)
5/99- Mo 799 (94 to 100)48 (40 to 56)100 (96 to 100)97 (93 to 99)100 (96 to 100)97 (94 to 99)98 (95 to 99)86 (78 to 93)
NZ98/254 Mo 022 (15 to 31)30 (24 to 36)27 (19 to 36)25 (20 to 31)24 (16 to 33)26 (21 to 32)25 (20 to 30)29 (21 to 38)
NZ98/254 Mo 184 (76 to 90)83 (77 to 87)82 (74 to 89)84 (79 to 88)75 (65 to 82)80 (74 to 85)86 (81 to 89)26 (18 to 35)
NZ98/254 Mo 272 (62 to 80)70 (64 to 76)98 (93 to 100)99 (97 to 100)65 (55 to 74)75 (68 to 80)99 (97 to 100)31 (23 to 41)
NZ98/254 Mo 370 (60 to 79)65 (58 to 71)90 (82 to 95)91 (86 to 94)98 (93 to 100)100 (97 to 100)98 (96 to 99)30 (21 to 39)
NZ98/254 Mo 660 (49 to 69)54 (47 to 62)80 (71 to 87)77 (70 to 82)86 (77 to 92)86 (80 to 90)91 (87 to 94)38 (28 to 48)
NZ98/254 Mo 799 (94 to 100)49 (42 to 57)99 (94 to 100)71 (64 to 78)100 (96 to 100)81 (74 to 86)84 (79 to 88)86 (78 to 93)
SecondaryPercentages of Subjects With at Least a Fourfold Rise in hSBA Titer Over the Prevaccination and After Booster Vaccination.

Immunogenicity was evaluated by measuring the percentage of subjects with at least a fourfold rise in hSBA titer over the prevaccination and after booster vaccination against 44/76-SL, 5/99, NZ98/254 strains at month-1, month-2, month-3 and month-7.

Time frame:
Month-1, month-2, month-3 and month-7
Reported as:
Number · percentage of Subjects
Percentages of Subjects With at Least a Fourfold Rise in hSBA Titer Over the Prevaccination and After Booster Vaccination.
percentage of SubjectsrMenB06rMenB0rMenB016rMenB01rMenB026rMenB02rMenB012rMenB6
44/76-SL Mo 173 (64 to 81)75 (69 to 80)71 (61 to 79)77 (71 to 82)67 (58 to 76)73 (67 to 79)72 (67 to 77)3 (1 to 7)
44/76-SL Mo 262 (52 to 71)67 (60 to 73)94 (88 to 98)96 (92 to 98)65 (55 to 74)61 (54 to 67)94 (91 to 97)6 (2 to 12)
44/76-SL Mo 353 (43 to 63)59 (52 to 66)88 (81 to 94)91 (87 to 95)91 (84 to 96)95 (92 to 98)95 (92 to 97)3 (1 to 8)
44/76-SL Mo 795 (89 to 99)33 (26 to 40)98 (93 to 100)73 (66 to 79)93 (86 to 98)76 (69 to 82)80 (75 to 85)76 (66 to 84)
5/99 Mo 187 (80 to 93)79 (73 to 84)81 (72 to 87)85 (80 to 89)79 (70 to 86)85 (80 to 89)85 (80 to 88)3 (1 to 7)
5/99 Mo 278 (69 to 85)65 (58 to 72)98 (93 to 100)98 (95 to 100)63 (53 to 72)74 (68 to 80)98 (96 to 99)5 (2 to 10)
5/99 Mo 365 (56 to 74)53 (46 to 60)95 (89 to 98)99 (96 to 100)96 (91 to 99)99 (96 to 100)99 (98 to 100)6 (3 to 13)
5/99- Mo 798 (92 to 100)27 (21 to 34)99 (94 to 100)88 (82 to 92)99 (94 to 100)90 (85 to 94)94 (90 to 97)82 (73 to 89)
NZ98/254 Mo 172 (63 to 80)70 (63 to 76)65 (56 to 74)74 (67 to 79)59 (49 to 68)64 (58 to 70)73 (68 to 78)3 (1 to 7)
NZ98/254 Mo 257 (47 to 67)52 (45 to 59)89 (81 to 94)93 (89 to 96)51 (41 to 61)57 (50 to 64)93 (89 to 95)7 (3 to 14)
NZ98/254 Mo 350 (40 to 59)43 (36 to 50)78 (69 to 85)81 (76 to 86)91 (84 to 96)91 (86 to 94)93 (90 to 96)6 (3 to 13)
NZ98/254 Mo 794 (87 to 98)27 (21 to 35)95 (88 to 98)62 (55 to 69)92 (85 to 97)69 (62 to 76)75 (69 to 80)77 (67 to 85)
SecondaryGeometric Mean Titers (GMTs) After Primary and Booster Vaccination.

Immunogenicity was evaluated by measuring the Geometric mean titers (GMTs) after primary and booster vaccination against 44/76-SL, 5/99, NZ98/254.

Time frame:
month-1, month-2, month-3, month-6 and month-7
Reported as:
Geometric mean · Titers
Geometric Mean Titers (GMTs) After Primary and Booster Vaccination.
TitersrMenB06rMenB0rMenB016rMenB01rMenB026rMenB02rMenB012rMenB6
44/76 GMT Mo 03.41 (2.54 to 4.58)4.24 (3.44 to 5.22)3.34 (2.49 to 4.48)3.35 (2.72 to 4.11)3.39 (2.52 to 4.56)3.99 (3.25 to 4.9)3.87 (3.26 to 4.6)3.89 (2.91 to 5.19)
44/76 GMT Mo 146 (33 to 63)58 (46 to 72)56 (40 to 77)52 (41 to 65)44 (32 to 61)57 (45 to 71)60 (49 to 72)3.39 (2.46 to 4.65)
44/76 GMT Mo 231 (23 to 41)41 (34 to 50)182 (138 to 240)187 (154 to 228)28 (21 to 37)38 (31 to 46)193 (164 to 228)4.09 (3.11 to 5.38)
44/76 GMT Mo 320 (16 to 26)31 (26 to 38)132 (101 to 172)114 (95 to 137)182 (139 to 236)230 (191 to 277)240 (205 to 280)4.04 (3.12 to 5.22)
44/76 GMT Mo 613 (9.24 to 18)15 (12 to 19)59 (43 to 82)50 (39 to 63)54 (39 to 75)75 (60 to 95)86 (70 to 104)3.9 (2.82 to 5.4)
44/76 GMT Mo 7218 (157 to 302)12 (9.69 to 15)324 (236 to 443)36 (29 to 45)259 (188 to 357)48 (38 to 60)59 (49 to 72)56 (41 to 77)
5/99 GMT Mo 02.61 (2.03 to 3.34)3.15 (2.64 to 3.75)2.59 (2.02 to 3.32)2.52 (2.11 to 2.99)2.43 (1.89 to 3.12)2.72 (2.29 to 3.24)2.58 (2.23 to 2.98)2.27 (1.78 to 2.89)
5/99 GMT Mo 181 (61 to 109)64 (52 to 79)66 (49 to 88)72 (59 to 88)57 (42 to 76)76 (62 to 93)71 (60 to 84)2.56 (1.93 to 3.4)
5/99 GMT Mo 240 (31 to 51)34 (28 to 40)505 (396 to 644)451 (381 to 535)26 (20 to 33)40 (34 to 48)481 (415 to 556)2.48 (1.95 to 3.16)
5/99 GMT Mo 325 (20 to 31)23 (20 to 27)303 (242 to 380)273 (233 to 320)540 (431 to 677)822 (702 to 964)584 (510 to 668)2.58 (2.07 to 3.22)
5/99 GMT Mo 612 (9.56 to 16)11 (9.26 to 13)125 (98 to 160)113 (95 to 135)124 (97 to 158)147 (123 to 175)186 (160 to 216)2.03 (1.59 to 2.59)
5/99 GMT Mo 7880 (675 to 1147)8.61 (7.13 to 10)1094 (849 to 1410)99 (82 to 119)994 (767 to 1289)121 (101 to 146)164 (141 to 192)53 (41 to 68)
NZ98/254 GMT Mo 02.87 (2.14 to 3.84)3.35 (2.72 to 4.13)3.43 (2.56 to 4.59)2.98 (2.43 to 3.66)3.07 (2.28 to 4.12)3.39 (2.76 to 4.16)2.83 (2.38 to 3.36)3.12 (2.34 to 4.15)
NZ98/254 GMT Mo142 (31 to 56)44 (36 to 55)47 (35 to 63)45 (36 to 55)37 (27 to 50)42 (34 to 52)49 (41 to 58)2.85 (2.11 to 3.84)
NZ98/254 GMT Mo 223 (17 to 30)25 (20 to 31)98 (72 to 132)89 (72 to 110)19 (14 to 26)26 (21 to 32)92 (77 to 110)3.28 (2.43 to 4.41)
NZ98/254 GMT Mo 317 (13 to 22)19 (16 to 24)61 (46 to 82)52 (42 to 64)117 (87 to 157)125 (102 to 154)122 (102 to 145)3.57 (2.68 to 4.75)
NZ98/254 GMT Mo 612 (8.94 to 17)11 (8.63 to 14)31 (22 to 42)29 (23 to 36)44 (32 to 61)49 (39 to 61)52 (43 to 63)4.17 (3.04 to 5.72)
NZ98/254 GMT Mo 7140 (101 to 195)10 (8.01 to 13)181 (132 to 248)24 (19 to 30)168 (122 to 232)39 (31 to 49)41 (34 to 50)47 (34 to 64)
SecondaryGeometric Mean Ratios (GMRs) After Primary and Booster Vaccination.

Immunogenicity was evaluated by measuring the Geometric mean ratios (GMRs) after primary and booster vaccination against 44/76-SL, 5/99, NZ98/254.

Time frame:
month-1, month-2, month-3, month-6 and month-7
Reported as:
Geometric mean · Ratio
Geometric Mean Ratios (GMRs) After Primary and Booster Vaccination.
RatiorMenB06rMenB0rMenB016rMenB01rMenB026rMenB02rMenB012rMenB6
44/76 GMR Mo 1 to 013 (10 to 18)14 (11 to 17)17 (12 to 22)16 (13 to 19)13 (9.71 to 18)14 (12 to 17)15 (13 to 18)0.89 (0.66 to 1.18)
44/76 GMR Mo 2 to 08.92 (6.73 to 12)9.65 (7.88 to 12)53 (40 to 71)56 (46 to 69)8.43 (6.33 to 11)9.51 (7.79 to 12)50 (42 to 59)1.04 (0.79 to 1.38)
44/76 GMR Mo 3 to 05.98 (4.51 to 7.92)7.31 (5.97 to 8.96)37 (28 to 50)34 (28 to 42)55 (41 to 73)58 (48 to 71)62 (52 to 73)0.98 (0.74 to 1.3)
44/76 GMR Mo 6 to 03.98 (2.96 to 5.35)3.64 (2.93 to 4.52)17 (13 to 23)16 (13 to 19)16 (12 to 21)20 (16 to 25)23 (19 to 27)0.92 (0.69 to 1.24)
44/76 GMR Mo 7 to 074 (54 to 103)3.09 (2.46 to 3.88)92 (67 to 125)12 (9.24 to 14)79 (58 to 109)13 (11 to 17)16 (13 to 19)13 (9.76 to 18)
44/76 GMR Mo 7 to 618 (14 to 23)0.89 (0.76 to 1.05)5.36 (4.3 to 6.68)0.72 (0.61 to 0.84)5.08 (4.05 to 6.37)0.67 (0.57 to 0.79)0.67 (0.59 to 0.77)14 (11 to 17)
5/99 GMR Mo 1 to 031 (23 to 42)20 (16 to 25)25 (19 to 34)29 (23 to 35)23 (17 to 32)28 (23 to 34)28 (23 to 33)1.13 (0.84 to 1.52)
5/99 GMR Mo 2 to 015 (11 to 20)11 (8.65 to 13)198 (149 to 262)181 (149 to 220)11 (8.13 to 14)15 (12 to 18)186 (158 to 220)1.06 (0.8 to 1.4)
5/99 GMR Mo 3 to 09.22 (6.94 to 12)7.37 (6.01 to 9.04)115 (86 to 153)109 (89 to 133)233 (175 to 311)306 (250 to 374)225 (190 to 267)1.09 (0.82 to 1.44)
5/99 GMR Mo 6 to 04.65 (3.47 to 6.23)3.83 (3.09 to 4.75)49 (37 to 66)45 (36 to 55)52 (39 to 70)56 (45 to 69)74 (62 to 88)0.82 (0.61 to 1.1)
5/99 GMR Mo 7 to 0355 (254 to 497)3.07 (2.42 to 3.89)430 (312 to 594)40 (32 to 50)427 (307 to 593)46 (36 to 58)65 (53 to 79)21 (16 to 29)
5/99 GMR Mo 7 to 671 (55 to 90)0.83 (0.7 to 0.99)8.98 (7.13 to 11)0.87 (0.74 to 1.03)7.92 (6.26 to 10)0.83 (0.71 to 0.99)0.86 (0.74 to 0.99)26 (20 to 32)
NZ98/254 GMR Mo 1 to 014 (11 to 19)13 (11 to 16)14 (10 to 18)15 (12 to 18)12 (9 to 16)12 (10 to 15)17 (15 to 21)0.91 (0.68 to 1.2)
NZ98/254 GMR Mo 2 to 07.69 (5.86 to 10)7.24 (5.97 to 8.79)29 (22 to 38)30 (24 to 36)6.46 (4.91 to 8.5)7.96 (6.57 to 9.63)33 (28 to 39)1.06 (0.81 to 1.38)
NZ98/254 GMR Mo 3 to 06.01 (4.54 to 7.96)5.5 (4.49 to 6.74)18 (14 to 24)18 (14 to 21)40 (30 to 54)38 (32 to 47)44 (37 to 52)1.13 (0.86 to 1.5)
NZ98/254 GMR Mo 6 to 04.75 (3.62 to 6.24)3.49 (2.86 to 4.26)9.26 (7.05 to 12)10 (8.29 to 12)14 (11 to 19)15 (13 to 19)19 (16 to 22)1.28 (0.98 to 1.68)
NZ98/254 GMR Mo 7 to 059 (44 to 80)3.32 (2.67 to 4.12)53 (40 to 71)8.94 (7.26 to 11)57 (42 to 77)13 (10 to 16)15 (12 to 18)15 (11 to 19)
NZ98/254 GMR Mo 7 to 611 (8.73 to 14)0.99 (0.84 to 1.17)5.86 (4.7 to 7.3)0.85 (0.73 to 1)3.95 (3.15 to 4.95)0.84 (0.72 to 0.99)0.81 (0.7 to 0.92)11 (8.98 to 14)
SecondaryGMCs of Antibodies Against 287-953Antigen (ELISA) After Primary and Booster Vaccination.

Immunogenicity was evaluated by measuring the Geometric mean Concentration (GMCs) after primary and booster vaccination against Antigen 287-953 Antigen.

Time frame:
month-1, month-2, month-3, month-6 and month-7
Reported as:
Geometric mean · IU/ml
GMCs of Antibodies Against 287-953Antigen (ELISA) After Primary and Booster Vaccination.
IU/mlrMenB06rMenB0rMenB016rMenB01rMenB026rMenB02rMenB012rMenB6
GMC Mo 035 (25 to 51)35 (25 to 50)43 (30 to 61)37 (26 to 54)44 (31 to 63)32 (23 to 46)32 (22 to 45)48 (34 to 68)
GMC Mo 1190 (113 to 318)204 (123 to 340)334 (200 to 555)217 (130 to 361)234 (140 to 389)220 (132 to 367)521 (313 to 868)50 (30 to 82)
GMC Mo 2173 (115 to 261)154 (102 to 231)3025 (2015 to 4543)3875 (2566 to 5854)175 (117 to 263)144 (96 to 216)3693 (2459 to 5545)42 (28 to 62)
GMC Mo 3102 (69 to 152)124 (84 to 183)1612 (1093 to 2378)1831 (1234 to 2716)3332 (2259 to 4916)2936 (1990 to 4332)5314 (3602 to 7839)42 (29 to 62)
GMC Mo 691 (59 to 138)72 (48 to 110)565 (372 to 857)488 (322 to 741)807 (531 to 1224)628 (414 to 953)1602 (1055 to 2431)37 (24 to 56)
GMC Mo 72240 (1385 to 3623)69 (43 to 112)3840 (2391 to 6168)383 (237 to 620)5492 (3419 to 8821)532 (331 to 855)1111 (692 to 1785)283 (176 to 454)
SecondaryGMRs of Antibodies Against 287-953Antigen (ELISA) After Primary and Booster Vaccination

Immunogenicity was evaluated by measuring the Geometric mean Ratios (GMRs) after primary and booster vaccination against 287-953Antigen

Time frame:
month-1, month-2, month-3, month-6 and month-7
Reported as:
Geometric mean · Ratio
GMRs of Antibodies Against 287-953Antigen (ELISA) After Primary and Booster Vaccination
RatiorMenB06rMenB0rMenB016rMenB01rMenB026rMenB02rMenB012rMenB6
GMR Mo 1 to 05.73 (3.19 to 9.05)5.82 (3.48 to 9.73)7.75 (4.64 to 13)5.34 (3.12 to 9.14)5.26 (3.14 to 8.79)6.85 (4.09 to 11)16 (9.77 to 27)1.03 (0.62 to 1.73)
GMR Mo 2 to 04.9 (3.2 to 7.5)4.38 (2.88 to 6.66)70 (46 to 107)112 (72 to 175)3.94 (2.59 to 5.99)4.46 (2.93 to 6.79)116 (76 to 176)0.87 (0.57 to 1.32)
GMR Mo 3 to 02.9 (1.82 to 4.61)3.54 (2.24 to 5.59)37 (24 to 59)55 (34 to 89)75 (47 to 118)91 (58 to 144)167 (105 to 263)0.88 (0.56 to 1.4)
GMR Mo 6 to 02.56 (1.59 to 4.13)2.06 (1.29 to 3.3)13 (8.2 to 21)13 (7.86 to 21)18 (11 to 29)20 (12 to 31)50 (31 to 80)0.77 (0.48 to 1.23)
GMR Mo 7 to 063 (34 to 119)1.94 (1.03 to 3.64)89 (48 to 166)11 (5.67 to 21)123 (66 to 229)17 (8.9 to 31)35 (19 to 65)5.9 (3.17 to 11)
SecondaryNumber of Subjects Reporting Unsolicited AEs Throughout the Study.

Safety was assessed as the number of subjects who reported unsolicited AEs throughout the study.

Time frame:
Throughout the study
Reported as:
Number · participants
Number of Subjects Reporting Unsolicited AEs Throughout the Study.
participantsrMenB06rMenB0rMenB016rMenB01rMenB026rMenB02rMenB012rMenB6
Any AE's65137731437214821080
At least possibly related AEs2236303624437626
Serious AEs542424113
At least possibly related SAEs00000020
AEs leading to discontinuation10001010
Post-hocPercentage of Subjects With hSBA Titers≥4 After Receiving Second Dose of Vaccination

Immunogenicity was evaluated by measuring the percentage of subjects with hSBA titter \>1:4 against M10713 strain at 1 month after second dose of vaccination (Month 3)

Time frame:
At one month after second dose (Month 3)
Reported as:
Number · Percentage of subjects
Percentage of Subjects With hSBA Titers≥4 After Receiving Second Dose of Vaccination
Percentage of subjectsrMenB01rMenB02
Baseline96 (85 to 99)80 (66 to 91)
1 month after second dose100 (92 to 100)100 (92 to 100)

Adverse events

Collected over Solicited adverse events (AEs) were collected from Day 1 through 7,Serious AEs were collected throughout the study.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
rMenB06—5/128 (3.9%)123/128 (96.1%)
rMenB0—4/247 (1.6%)238/247 (96.4%)
rMenB016—2/128 (1.6%)126/128 (98.4%)
rMenB01—4/247 (1.6%)242/247 (98%)
rMenB026—2/127 (1.6%)118/127 (92.9%)
rMenB02—4/253 (1.6%)240/253 (94.9%)
rMenB012—11/373 (2.9%)354/373 (94.9%)
rMenB6—3/128 (2.3%)125/128 (97.7%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventrMenB06rMenB0rMenB016rMenB01rMenB026rMenB02rMenB012rMenB6
TOXICITY TO VARlOUS AGENTSInjury, poisoning and procedural complications0/1280/2470/1280/2470/1272/2530/3730/128
APPENDICITISInfections and infestations1/1281/2471/1281/2471/1271/2532/3731/128
MAJOR DEPRESSIONPsychiatric disorders0/1280/2470/1280/2471/1270/2530/3730/128
PANIC ATTACKPsychiatric disorders0/1280/2470/1280/2471/1270/2530/3730/128
SUICIDE ATTEMPTPsychiatric disorders0/1281/2470/1280/2471/1270/2530/3731/128
PNEUMONIA VIRALInfections and infestations1/1280/2470/1280/2470/1270/2530/3730/128
ROAD TRAFFIC ACCIDENTInjury, poisoning and procedural complications1/1280/2470/1280/2470/1270/2530/3730/128
ADENOMA BENIGNNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1280/2470/1280/2470/1270/2530/3731/128
CONVULSIONNervous system disorders1/1281/2470/1280/2470/1270/2530/3730/128
PREMATURE LABOURPregnancy, puerperium and perinatal conditions1/1280/2471/1280/2470/1270/2530/3730/128
Most frequent other events
Showing 10 of 16
Most frequent other events
EventrMenB06rMenB0rMenB016rMenB01rMenB026rMenB02rMenB012rMenB6
INJECTION SITE PAINGeneral disorders122/128236/247124/128237/247113/127236/253345/373123/128
INJECTION SITE ERYTHEMAGeneral disorders93/128162/24797/128188/24794/127172/253282/37386/128
MALAISEGeneral disorders92/128181/24796/128172/24787/127185/253272/37389/128
MYALGIAMusculoskeletal and connective tissue disorders85/128141/24791/128158/24782/127160/253238/37391/128
HEADACHENervous system disorders79/128140/24788/128160/24774/127165/253244/37376/128
INJECTION SITE INDURATIONGeneral disorders72/128130/24776/128151/24782/127122/253228/37358/128
INJECTION SITE SWELLINGGeneral disorders73/128132/24781/128144/24776/127115/253226/37355/128
ARTHRALGIAMusculoskeletal and connective tissue disorders56/12876/24755/12881/24739/127105/253146/37344/128
NAUSEAGastrointestinal disorders41/12880/24751/12872/24742/12789/253143/37349/128
PYREXIAGeneral disorders12/1288/24713/12821/24718/12726/25338/37320/128

Baseline characteristics

Age, Continuous
Age, Continuous(years)rMenB06rMenB0rMenB016rMenB01rMenB026rMenB02rMenB012rMenB6Total
Mean13.8 ± 1.913.8 ± 1.913.9 ± 1.913.9 ± 1.913.7 ± 1.913.7 ± 1.813.8 ± 1.913.8 ± 213.8 ± 1.9
Sex: Female, Male
Sex: Female, Male(Participants)rMenB06rMenB0rMenB016rMenB01rMenB026rMenB02rMenB012rMenB6Total
Female76147761387313819966913
Male52100521095411517462718
08

Study locations

10 sites
  • Site 13: Liceo Diego Aracena de Lo Barnechea
    Monseñor Escrivá De Balaguer 14630, Lo Barnechea, Santiago, Chile
  • Site 41: Colegio Antonio Hermida Fabres
    Av. Coronel Alejandro Sepúlveda N° 6801, Chile
  • Site 43: Liceo José Victorino Lastarria
    Av. Miguel Claro N° 32, Chile
  • Site 51: Centro Para vacunas en Desarrollo. Hospital de Niños Roberto del Rio
    Av. Prof Zañartu 1085, Chile
  • Site 15: Liceo Carmela Carvajal de Prat
    Avda. Italia 980, Chile
  • Site 14: Colegio Parroquial Santa Rosa de Lo Barnechea
    Avda. Raúl Labbé Nº 13.799, Chile
  • Site 42: Centro Educacional Eduardo de la Barra
    Calle A, N° 6301, Chile
  • Site 61: Facultad de Medicina. Universidad de Valparaíso.
    Hontaneda # 2653. Valparaíso, Chile
  • Site 11: Complejo Educacional Eduardo Cuevas Valdés
    Lo Barnechea, Chile
  • Site 12: Colegio San Jose de Lo Barnechea
    Santiago, Chile
09

References and documents

Publications

  • Bartolini E, Borgogni E, Bruttini M, Muzzi A, Giuliani M, Iozzi S, Petracca R, Martinelli M, Bonacci S, Marchi S, Brettoni C, Donati C, Torricelli G, Guidotti S, Domina M, Beninati C, Teti G, Felici F, Rappuoli R, Castellino F, Del Giudice G, Masignani V, Pizza M, Maione D. Immunological fingerprint of 4CMenB recombinant antigens via protein microarray reveals key immunosignatures correlating with bactericidal activity. Nat Commun. 2020 Oct 5;11(1):4994. doi: 10.1038/s41467-020-18791-0. PubMed 33020485 ↗
  • Santolaya ME, O'Ryan ML, Valenzuela MT, Prado V, Vergara R, Munoz A, Toneatto D, Grana G, Wang H, Clemens R, Dull PM; V72P10 Meningococcal B Adolescent Vaccine Study group. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet. 2012 Feb 18;379(9816):617-24. doi: 10.1016/S0140-6736(11)61713-3. Epub 2012 Jan 18. Erratum In: Lancet. 2015 May 2;385(9979):1728. doi: 10.1016/S0140-6736(14)62411-9. PubMed 22260988 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2008, a primary completion of Apr 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2015, 5 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2008
First posted
Apr 18, 2008
Start
Jun 2008
Primary completionActual
Apr 2010
CompletionActual
Dec 2010
Results first posted
Nov 4, 2015
Last update
Mar 20, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00661713
Lead sponsor
Novartis Vaccines
Responsible party
Sponsor
First posted
Apr 18, 2008
Start date
Jun 2008
Primary completion
Apr 2010
Completion
Dec 2010
Results posted
Nov 4, 2015
Last update
Mar 20, 2019

Study contacts

Novartis Vaccines
study chair · Novartis Vaccines
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 4CMenB vaccine

Start the discussion